All Updates

All Updates

icon
Filter
Product updates
Foundation Medicine launches FoundationOne Monitor
Precision Medicine
Jun 2, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Precision Medicine

Precision Medicine

Jun 2, 2023

Foundation Medicine launches FoundationOne Monitor

Product updates

  • Companion diagnostics developer Foundation Medicine has launched FoundationOne Monitor, a tissue-naïve circulating tumor DNA (ctDNA) monitoring assay for research use in retrospective studies. The product provides insights into treatment response, resistance mechanisms, and ctDNA tumor fraction when tumor tissue is not available.

  • FoundationOne Monitor quantifies ctDNA tumor fraction at each time point, offering molecular response insights and assessing resistance to therapy across more than 300 genes. It complements standard imaging in early-phase clinical research and expands Foundation Medicine's monitoring portfolio. Also included in Foundation Medicine's monitoring portfolio is FoundationOne Tracker, a ctDNA test that utilizes tissue information which was launched in June 2021 for research purposes and in January 2023 for investigational use.

  • The key benefits of using FoundationOne Monitor include improved sensitivity, high specificity, and comprehensive insights on treatment response, variant studies, resistance mechanisms, and ctDNA tumor fraction. It complements the existing monitoring portfolio and positions Foundation Medicine as a one-stop shop for biopharma partners' treatment response in monitoring research needs.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.